Oculomotor Deficits after Chemotherapy in Childhood.

Einar-Jón Einarsson, Mitesh Patel, Hannes Petersen, Thomas Wiebe, Måns Magnusson, Christian Moëll, Per-Anders Fransson

Rannsóknarafurð: Framlag til fræðitímaritsGreinritrýni


Advances in the diagnosis and treatment of pediatric malignancies have substantially increased the number of childhood cancer survivors. However, reports suggest that some of the chemotherapy agents used for treatment can cross the blood brain barrier which may lead to a host of neurological symptoms including oculomotor dysfunction. Whether chemotherapy at young age causes oculomotor dysfunction later in life is unknown. Oculomotor performance was assessed with traditional and novel methods in 23 adults (mean age 25.3 years, treatment age 10.2 years) treated with chemotherapy for a solid malignant tumor not affecting the central nervous system. Their results were compared to those from 25 healthy, age-matched controls (mean age 25.1 years). Correlation analysis was performed between the subjective symptoms reported by the chemotherapy treated subjects (CTS) and oculomotor performance. In CTS, the temporal control of the smooth pursuit velocity (velocity accuracy) was markedly poorer (p<0.001) and the saccades had disproportionally shorter amplitude than normal for the associated saccade peak velocity (main sequence) (p = 0.004), whereas smooth pursuit and saccade onset times were shorter (p = 0.004) in CTS compared with controls. The CTS treated before 12 years of age manifested more severe oculomotor deficits. CTS frequently reported subjective symptoms of visual disturbances (70%), unsteadiness, light-headedness and that things around them were spinning or moving (87%). Several subjective symptoms were significantly related to deficits in oculomotor performance. To conclude, chemotherapy in childhood or adolescence can result in severe oculomotor dysfunctions in adulthood. The revealed oculomotor dysfunctions were significantly related to the subjects' self-perception of visual disturbances, dizziness, light-headedness and sensing unsteadiness. Assessments of oculomotor function may, thus, offer an objective method to track and rate the level of neurological complications following chemotherapy.
Upprunalegt tungumálEnska
FræðitímaritPLoS ONE
ÚtgáfustaðaÚtgefið - 2016

Önnur efnisorð

  • Krabbamein
  • Börn
  • Meðferð
  • OTO12
  • Drug Therapy/adverse effects
  • Neoplasms
  • Child
  • Child, Preschool
  • Eye Movements


Sökktu þér í rannsóknarefni „Oculomotor Deficits after Chemotherapy in Childhood.“. Saman myndar þetta einstakt fingrafar.

Vitna í þetta